Femasys (FEMY) said Thursday that the US Patent and Trademark Office has granted a notice of allowance for an application covering the use of FemaSeed for female infertility treatment.
The company said it expects the patent to last until at least 2044.
Femasys added that it plans to file more patent applications to protect FemaSeed, FemBloc permanent birth control, and other diagnostic products, such as FemVue, FemCath, and FemCerv.
Shares of Femasys rose past 4% in recent trading activity.
Price: 1.11, Change: +0.05, Percent Change: +4.72
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.